<sup>68</sup>Ga-PSMA PET/CT has been routinely utilized in patients with intermediate to high-risk category prostate carcinoma for staging, biochemical recurrence and before planning the PSMA radioligand therapy (RLT). The gene discussed is FOLH1; the disease is prostate carcinoma.